Income Taxes	3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 7. Income Taxes The Company recorded a tax benefit of $4 million for the three months ended March 31, 2020. For interim periods, income tax is equal to the total of (1) year-to-date pretax income multiplied by our forecasted effective tax rate plus (2) tax expense items specific to the period. In situations where we expect to report losses that we do not expect to receive a tax benefit, we are required to apply separate forecasted effective tax rates to those jurisdictions, rather than including them in the consolidated effective tax rate. For the three months ended March 31, 2020, income tax expense was impacted by this set of rules, resulting in an additional cost of $1 million compared to what would have been recorded under the general rule on a consolidated basis. For the three months ended March 31, 2020, the net tax benefit of $4 million, was driven by tax expense specific to the period of approximately $17 million primarily related to $15 million for valuation allowances in foreign jurisdictions and $2 million related to the estimated tax impact of the CARES Act on prior years, offset by the impact of our estimated annual effective tax rate applied to pre-tax losses. In addition to items specific to the period our income tax rate is impacted by the mix of earnings across the jurisdictions in which we operate, non-deductible expenses, and U.S. taxation of foreign earnings.

Income Taxes

3 Months Ended

Mar. 31, 2020

Note 7. Income Taxes

The Company recorded a tax benefit of $4 million for the three months ended March 31, 2020.

For interim periods, income tax is equal to the total of (1) year-to-date pretax income multiplied by our forecasted effective tax rate plus (2) tax expense items specific to the period. In situations where we expect to report losses that we do not expect to receive a tax benefit, we are required to apply separate forecasted effective tax rates to those jurisdictions, rather than including them in the consolidated effective tax rate. For the three months ended March 31, 2020, income tax expense was impacted by this set of rules, resulting in an additional cost of $1 million compared to what would have been recorded under the general rule on a consolidated basis.

For the three months ended March 31, 2020, the net tax benefit of $4 million, was driven by tax expense specific to the period of approximately $17 million primarily related to $15 million for valuation allowances in foreign jurisdictions and $2 million related to the estimated tax impact of the CARES Act on prior years, offset by the impact of our estimated annual effective tax rate applied to pre-tax losses. In addition to items specific to the period our income tax rate is impacted by the mix of earnings across the jurisdictions in which we operate, non-deductible expenses, and U.S. taxation of foreign earnings.